Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.